ArticlePloS one2025
Disrupting ribulose-5-phosphate metabolic flux enhances riboflavin production in Escherichia coli BL21(DE3).
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Riboflavin (vitamin B2) is an essential water-soluble vitamin. To increase its production in a previously engineered strain, R203, we employed metabolic engineering strategies to improve the supply of ribulose-5-phosphate, a key precursor. Disruption of the genes pfkA and edd-eda, which are aimed at promoting ribulose-5-phosphate generation, increased riboflavin production by 51.27% and 65.81%, respectively. To minimize the consumption of ribulose-5-phosphate, we disrupted kdsD and gutQ, both of which encode D-arabinose 5-phosphate isomerase. Only the disruption of gutQ was effective, increasing production by 19.65%, whereas kdsD disruption had no significant effect. Furthermore, disrupting yajO and inserting the pgl gene increased production by 8.65% and 18.80%, respectively. In contrast, inserting ribM, which encodes a riboflavin transporter from Streptomyces davawensis, reduced production. The final engineered strain, R19, achieved a riboflavin titer of 2,546.35 ± 159.65 mg/L, representing a 287.35% increase over that of the starting strain. This study provides an effective strategy for high-level riboflavin production in recombinant Escherichia coli BL21(DE3) strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.